Pressure BioScience (OTCQB: PBIO) (“PBI”), a leader in
the development and sale of broadly enabling, pressure-based instruments,
consumables, and platform technology solutions to the worldwide biotechnology,
biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage
industries, today announced a letter of intent (“LOI”) to acquire SkinScience
Labs, Inc., parent company of the award-winning Dr. Denese skin care and
anti-aging product lines. Per the update, the rights to acquire SkinScience
Labs, which includes Dr. Denese SkinScience, is through Cannaworx, Inc., for
which PBI announced plans to acquire on April 28, 2020. “The Dr. Denese
SkinScience brand has reached top performing status on QVC for a skin care
line, selling over 25 million units and receiving multiple QVC customer choice
beauty awards,” PBI President and CEO Richard T. Schumacher said in the news
release. “Adrienne’s tremendous brand recognition, regularly repeating customer
base, and major existing sales momentum brings immediate accretive impact into
the PBI portfolio – and we know that our UST nanoemulsions will create powerful
new leverage and opportunities for her expanding product lines. Our team has
worked very hard to bring this pivotal transition together for PBI and its
shareholders, and we are very excited about the prospects for growth and value
appreciation in our combined companies going forward.”
To view the full press release, visit http://ibn.fm/7E2GG
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale
of innovative, broadly enabling, pressure-based solutions for the worldwide
life-sciences industry. The company’s products are based on the unique
properties of both constant (i.e., static) and alternating (i.e.,
pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented,
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil and plant biology, forensics and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired, patented technology from BaroFold
Inc. (the “BaroFold” technology) to allow entry into the biopharma contract
services sector, and (2) the use of its recently patented, scalable,
high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i)
create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and
water) and (ii) prepare higher-quality, homogenized, extended shelf-life or
room-temperature, stable, low-acid liquid foods that cannot be effectively
preserved using existing nonthermal technologies. For more information, visit
the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
